Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: Outcomes from the 4-Week...

Improvement Across Signs and Symptoms of Atopic Dermatitis with Lebrikizumab Use: Results from Two Phase 3, Randomized, Double-Blinded,...

Lebrikizumab Does Not Impact Vaccine-Induced Immune Responses: Results from A Phase 3 Study in Adult Patients with Moderate-to-Severe...

Assessing Imputation Methods with the Lebrikizumab Clinical Trial Program Authors: April W. Armstrong, Jonathan I. Silverberg, Jacob P....

Efficacy of Lebrikizumab in Patients with Atopic Dermatitis and Atopic Comorbidities: Pooled Results From 2 Phase 3 Monotherapy...

Patients with Moderate-to-Severe Atopic Dermatitis Experience Heterogeneous Disease Course Phenotypes: Results of a Real-World Study in...

Comparison of Two OTC Itch Relief Products After Single Application Authors: Christine Emesiani, PharmD; Matthew Meckfessel, PhD; Thu...

A Retrospective Multi-Center Case Series of Real-World Tralokinumab Use in Dupilumab-Experienced Patients Authors: Edward I. Herman, MD,...

Long-Term Safety and Efficacy of Tralokinumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: An interim analysis of ECZTEND...

Real-World Patient Characteristics and Early Patient-Reported Outcomes in Adult Patients with Moderate-to-Severe Atopic Dermatitis...

A Retrospective Case Series of Real-World Tralokinumab Use in Patients with Moderate-to-Severe Atopic Dermatitis Resistant to Systemic...

Long-Term Efficacy of Abrocitinib in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE EXTEND...

Clinically Important Benefits in Infants and Young Children with Moderate-to-Severe Atopic Dermatitis Not Achieving IGA 0/1 After 16...

Dupilumab Treatment in Patients with Hand and Foot Atopic Dermatitis: Results from a Phase 3, Randomized, Double-Blind,...

A Case Series of Live Attenuated Vaccine Administration in Dupilumab-Treated Children with Atopic Dermatitis Authors: Elaine C....

Long-Term Efficacy of Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label Extension Trial Up to 5...

Safety of Long-Term Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label Extension Trial...

Treatment-Emergent Adverse Events in Patients Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab...